|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1QTNF2 |
Gene summary for C1QTNF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1QTNF2 | Gene ID | 114898 |
| Gene name | C1q and TNF related 2 | |
| Gene Alias | CTRP2 | |
| Cytomap | 5q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q9BXJ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114898 | C1QTNF2 | HCC1 | Human | Liver | HCC | 8.49e-03 | 2.98e-01 | 0.5336 |
| 114898 | C1QTNF2 | HCC2 | Human | Liver | HCC | 7.14e-07 | 5.17e-01 | 0.5341 |
| 114898 | C1QTNF2 | HCC5 | Human | Liver | HCC | 2.62e-11 | 7.87e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00192162 | Liver | HCC | regulation of lipid metabolic process | 181/7958 | 331/18723 | 4.58e-06 | 5.79e-05 | 181 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1QTNF2 | SNV | Missense_Mutation | novel | c.779A>C | p.Asn260Thr | p.N260T | Q9BXJ5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| C1QTNF2 | SNV | Missense_Mutation | c.956N>A | p.Leu319Gln | p.L319Q | Q9BXJ5 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| C1QTNF2 | insertion | Nonsense_Mutation | novel | c.808_809insGAATCTTGCTCTGTCGCCCAGGCTAGAGTGCAGT | p.Ala270GlyfsTer9 | p.A270Gfs*9 | Q9BXJ5 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| C1QTNF2 | SNV | Missense_Mutation | rs750083087 | c.907G>A | p.Gly303Arg | p.G303R | Q9BXJ5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C1QTNF2 | SNV | Missense_Mutation | c.856N>G | p.Leu286Val | p.L286V | Q9BXJ5 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1QTNF2 | SNV | Missense_Mutation | c.905A>G | p.Asn302Ser | p.N302S | Q9BXJ5 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C1QTNF2 | SNV | Missense_Mutation | rs761209993 | c.217C>T | p.Arg73Trp | p.R73W | Q9BXJ5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.219) | TCGA-AP-A1E3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| C1QTNF2 | SNV | Missense_Mutation | rs761209993 | c.217N>T | p.Arg73Trp | p.R73W | Q9BXJ5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.219) | TCGA-AX-A3GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| C1QTNF2 | SNV | Missense_Mutation | c.903N>T | p.Gln301His | p.Q301H | Q9BXJ5 | protein_coding | tolerated(0.13) | probably_damaging(0.996) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| C1QTNF2 | SNV | Missense_Mutation | novel | c.569N>A | p.Ser190Asn | p.S190N | Q9BXJ5 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |